1. Case Report: Evidence for Transplacental Transfer of Maternally Administered Infliximab to the Newborn 
Eric A. Vasiliauskas, Joseph A. Church, Neil Silverman, Mary Barry, Stephan R. Targan, Marla C. Dubinsky 
Clinical Gastroenterology and Hepatology 
Volume 4, Issue 10, Pages (October 2006)
DOI: /j.cgh
Copyright © 2006 American Gastroenterological Association (AGA) Institute Terms and Conditions

2. Figure 1
Infliximab levels over time. Initial maternal and child serum infliximab levels were measured 6 weeks after delivery. Breast-feeding was transiently discontinued at week 7, and the newborn’s drug levels decreased during the following weeks. The mother was again treated with 10 mg/kg of infliximab at week 10 because of a flare of her CD. Despite resumption of breast-feeding at that point, infliximab levels in her child continued to drop, albeit very slowly over time.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association (AGA) Institute Terms and Conditions

3. Figure 2 Paired maternal serum and breast milk infliximab levels.
Clinical Gastroenterology and Hepatology 2006 4, DOI: ( /j.cgh )
Copyright © 2006 American Gastroenterological Association (AGA) Institute Terms and Conditions